Menu

Alternative to formaldehyde in fluid preservation of biological specimens

Alternative to formaldehyde in fluid preservation of biological specimens

Type of measure: Substitution

A study had the aim to determine the suitability of biocides used in the pharmaceutical and cosmetic industry to preserve biological specimens. The biocide was assessed according to six parameters: antiseptic range, water/fat solubility coefficient, pH range, stability/reactivity, toxicity and flammability.A biocide out of range of the present parameters was not considered to be a suitable alternative. First, the substances were assessed according to the technical parameters. The substances that passed these were assessed according to the safety parameters. Twenty-two substances were reviewed according to this process.

The study concluded, that most biocides used in food, cosmetic and pharmaceutical products are not considered to be suitable for preservation of biological specimens. DMDM-hydantoin passes all 6 parameters, but DMDM-hydantoin has never been used for this purpose and therefore its long term effect on the integrity of the specimens is not known.

Published July 26, 2023
Please note that this substance or some of it's compounds are listed in Annex XIV (REACH regulation). This substance some of it's compounds are only allowed to be used, imported, or brought into the market, if authorisation requirements of REACH are fulfilled.
Please be aware that for this carcinogen you need to be more cautious when determining potential skin contact and how to regard dermal exposure in your risk reduction strategy.
Relevance
Carcinogens involved:
Formaldehyde
About this case
For more information please contact:
SUBSPORTplus Team
General facts

Facts about cancer-causing agents:

  • The direct costs of carcinogen exposure at work across Europe are estimated at 2.4 billion Euros per year.
  • Every year, about 120.000 persons get cancer from exposure to carcinogens at work
  • Annually more than 100.000 people die because of work-related cancer.